Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

Blood

Volumn 96, Issue 8, 2000, Pages 2691-2696

  Coustan Smith, Elaine ^a   Sancho, Jose ^a   Hancock, Michael L ^a   Boyett, James M ^a   Behm, Frederick G ^a   Raimondi, Susana C ^a   Sandlund, John T ^a   Rivera, Gaston K ^a   Rubnitz, Jeffrey E ^a   Ribeiro, Raul C ^a   Pui, Ching Hon ^a   Campana, Dario ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME;

EID: 0034667685     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.8.2691.h8002691_2691_2696     Document Type: Article

References (35)

1. Drug therapy: Acute lymphoblastic leukemia
2. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance
3. Detection of minimal residual disease in acute leukemia by flow cytometry
4. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis
5. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
6. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry
7. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
8. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia
9. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome
10. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group
11. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
12. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
13. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia
14. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study
15. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
16. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup
17. Cytogenetics of acute lymphoblastic leukaemia in children as a factor in the prediction of long-term survival
18. Prognostic importance of chromosome number in 136 untreated children with acute lymphoblastic leukemia
19. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study
20. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
21. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)
22. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia
23. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: Clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia
24. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
25. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
26. Induction failure in acute lymphoblastic leukemia of childhood
27. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia
28. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
29. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
30. Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Childrens Cancer Group
31. Persistence of lymphoblasts in bone marrow on day 15 and day 22-25 of remission induction predicted a poorer treatment outcome in children with acute lymphoblastic leukemia
32. Identification of novel leukemia markers by comparative analysis of gene expression with DNA microarrays
33. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis
34. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia